Sarepta Therapeutics SRPT · NASDAQ
$17.10 -3.88% (-$0.69)
Summary
51 / 100 · Bulios Score
What speaks for it
- Revenue grew by 33% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 16% this fiscal year.
- It passes only 3 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 32% a year over 5 years. Over the last 3 years it grew by 33% a year. For the next fiscal year analysts expect revenue to fall by 16%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $136.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 31
- Hold 18
- Sell 6
Today's price within the analysts' price targets
The average target of $22.75 is 33% above today's price. 56% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 84%
- Non-US 16%
UNITED STATES brings in 84% of revenue. Non-US grew fastest, by 20% a year.
Segments in detail